Major Finding: Sustained virologic response
to treatment was achieved in 58.2% of patients treated via telemedicine at Extension for Community Healthcare Outcomes (ECHO) sites, which was not significantly different from the 57.5% response rate of patients treated at an academic medical center.
The 77-center European study defined a sustained virologic response
as a hepatitis C virus (HCV) RNA level of less than 25 IU / mL, noted Dr.
CHICAGO -- The addition of telaprevir to standard hepatitis C treatment substantially improved sustained virologic response
rates across all IL28B genotypes in an unplanned post hoc analysis of the phase III ADVANCE trial.
The Walgreens Connected Care is an education and support plan designed to help patients achieve a sustained virologic response
(SVR) and improved quality of life through medication adherence through access to new advances in treatment therapy under the Affordable Care Act.
The primary efficacy endpoint was a sustained virologic response
(defined as an HCV RNA level of less than 25 IU/mL) at week 12 after the end of treatment.
In three phase III studies of more than 2,000 treatment-naive and treatment-experienced patients, the addition of telaprevir, an HCV-specific protease inhibitor taken three times a day for up to 12 weeks, to pegylated interferon and ribavirin significantly increased the sustained virologic response
(SVR) rate, compared with pegylated interferon and ribavirin therapy.
Boceprevir, and the second drug, telaprevir, ushered in a new era for HCV treatments, with improved sustained virologic response
rates, but their trade-offs included additional side effects, drug-drug interactions, and increased cost, he noted.
Reportedly, this submission is based on results from a Phase III study demonstrating that the 24-week, all-oral, interferon-free and ribavirin-free regimen of daclatasvir (DCV) and asunaprevir (ASV) achieved an overall sustained virologic response
24 weeks after the end of treatment (SVR24) of 84.7% in Japanese patients with chronic hepatitis C (HCV) genotype 1b who were either interferon-ineligible/intolerant (87.4% SVR24) or non-responders (null and partial) to interferon-based therapies (80.5% SVR24).
Adding the protease inhibitor boceprevir to standard peginterferonribavirin therapy for chronic hepatitis C virus type 1 markedly improves the rate of sustained virologic response
, according to two reports.
The COBAS Ampliprep/COBAS TaqMan HCV v.2 test can be utilised to predict the probability of sustained virologic response
(SVR) early during a course of antiviral treatment, as well as to evaluate a patient's response to such therapy.
Sustained virologic response
(SVR) to boceprevir in treatment-naive patients was 67% for older patients and 57% for younger patients.
The trial will assess on-treatment antiviral responses and sustained virologic response
rates to the triple DAA combination regimen, with or without ribavirin.